CDC: Behavioral Therapy Recommended First for ADHD

Share this content:
CDC: Behavioral Therapy Recommended First for ADHD
CDC: Behavioral Therapy Recommended First for ADHD

WEDNESDAY, May 4, 2016 (HealthDay News) -- Behavior modification therapy is preferable to medication for treating children 2 to 5 years old who have attention-deficit/hyperactivity disorder (ADHD), U.S. health officials say.

For the report, U.S. Centers for Disease Control and Prevention researchers looked at annual health care claims starting in 2008 for at least five million young children (2 to 5 years old) insured by Medicaid and another one million young children with employer-sponsored insurance.

Overall, a little more than 75 percent of young children received ADHD medicine. Only 54 percent of children with Medicaid and 45 percent of those with employer insurance received any type of psychological services, which might have included parent training. The number of children with ADHD receiving psychological services has not changed over time, the agency said. The authors of the report emphasize that the CDC "is calling on doctors, nurses, and allied health professionals who treat young children with ADHD to support parents by explaining the benefits of behavior therapy and referring parents for training in behavior therapy."

"Behavior therapy has been shown to help improve symptoms in young children with ADHD and can be as effective as medicine, but without the side effects," Anne Schuchat, M.D., principal deputy director of the CDC, said during a media briefing. "Research has shown that the benefits of behavior therapy can last for years."

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »